Close

Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum Apr 10, 2024 04:05PM
Syndax Pharmaceuticals (SNDX) Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session Apr 8, 2024 07:22AM
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session Apr 8, 2024 07:00AM
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Apr 5, 2024 04:05PM
Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia Mar 28, 2024 07:00AM
View Older Stories

Mar 26, 2024 04:06PM Syndax Pharmaceuticals (SNDX) Granted FDA Priority Review of NDA for Revumenib
Mar 26, 2024 04:05PM Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
Mar 18, 2024 07:03AM Syndax Pharmaceuticals (SNDX) names Steven Closter as Chief Commercial Officer
Mar 18, 2024 07:00AM Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
Mar 1, 2024 04:05PM Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Feb 27, 2024 04:05PM Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
Feb 26, 2024 07:00AM Syndax Announces Participation at Two Upcoming Investor Conferences
Feb 20, 2024 04:05PM Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024
Feb 2, 2024 04:05PM Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Feb 1, 2024 04:10PM Syndax Announces Participation at Two Upcoming Investor Conferences
Jan 5, 2024 04:05PM Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 2, 2024 04:05PM Syndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference
Jan 2, 2024 07:01AM Syndax Pharmaceuticals (SNDX) Reports Updates and Anticipated 2024 Milestones
Jan 2, 2024 07:00AM Syndax Highlights Recent Updates and Anticipated 2024 Milestones
Dec 19, 2023 04:16PM Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
Dec 12, 2023 12:00PM Syndax Pharmaceuticals (SNDX) Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib
Dec 12, 2023 12:00PM Syndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting
Dec 11, 2023 07:30AM Syndax Pharmaceuticals (SNDX) Reports Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Trials
Dec 11, 2023 07:30AM Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials
Dec 10, 2023 05:00PM Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease
Dec 4, 2023 07:00AM Syndax to Host Investor Event to Discuss Axatilimab and Revumenib Data Updates at 65th ASH Annual Meeting
Dec 1, 2023 04:05PM Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 21, 2023 09:00AM Syndax Announces Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Selected as Late-Breaking Presentation at the 65th ASH Annual Meeting
Nov 7, 2023 07:00AM Syndax Announces Participation at Stifel Healthcare Conference
Nov 3, 2023 04:05PM Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 2, 2023 04:05PM Syndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
Nov 2, 2023 09:05AM Syndax Pharmaceuticals (SNDX) Reports Results from AGAVE-201 Trial of Axatilimab
Nov 2, 2023 09:00AM Syndax Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting
Nov 2, 2023 09:00AM Syndax Announces Updated Data Supporting Impressive Clinical Profile of Revumenib in Genetically-Defined Acute Leukemias to Be Presented at the 65th ASH Annual Meeting
Oct 26, 2023 07:00AM Syndax to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 2, 2023
Oct 24, 2023 07:00AM Syndax Pharmaceuticals (SNDX) to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program
Oct 24, 2023 07:00AM Syndax to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program
Oct 6, 2023 04:05PM Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Oct 2, 2023 07:04AM Syndax Pharmaceuticals (SNDX) Announces Pivotal AUGMENT-101 Trial of Revumenib in R/R KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy
Oct 2, 2023 07:00AM Syndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis
Sep 29, 2023 04:05PM Syndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023
Sep 1, 2023 04:05PM Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 31, 2023 04:05PM Syndax Announces Participation at the Citi 18th Annual BioPharma Conference
Aug 4, 2023 04:05PM Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 3, 2023 04:05PM Syndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
Jul 25, 2023 07:00AM Syndax to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 3, 2023
Jul 24, 2023 07:02AM Syndax Pharmaceuticals (SNDX) and Incyte (INCY) Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
Jul 24, 2023 07:00AM Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
Jul 7, 2023 04:13PM Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jun 2, 2023 04:05PM Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 24, 2023 07:00AM Syndax Announces Participation at Two Upcoming Investor Conferences
May 8, 2023 04:05PM Syndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
May 4, 2023 04:05PM Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 1, 2023 07:00AM Syndax to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 8, 2023
Apr 13, 2023 04:05PM Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
View Older Stories